Women's Dermatologic Society

By Dr. Susan Massick Due to the FDA’s concern regarding the high risk of teratogenicity associated with isotretinoin, the iPLEDGE program was introduced by the Isotretinoin Products Manufacturers Group (IPMG) and approved by the FDA in 2005 in an effort to prevent pregnancy and fetal exposure during isotretinoin treatment. Despite concerns raised by clinicians and the AAD regarding the program and its implementation, the FDA approved March 1, 2006, as the mandatory start date for iPLEDGE. i In 2007, the FDA gained the authority to determine which medications would require Risk Evaluation and Management Strategy (REMS) programs to mitigate risks associated with certain drugs. In 2010, the iPLEDGE program was updated to the iPLEDGE REMS program with mandatory participation of all isotretinoin drug manufacturers and mandatory registration of all health care providers and pharmacies in order to prescribe and dispense isotretinoin to patients. ii While th

By the WDS Academic Dermatology Committee   Question: Are there specific things I should negotiate for in academics?     Dear WDS Member, Great question! The best opportunity to negotiate and make adjustments to a contract is often prior to signing with an institution. The approach will not be one-size-fits-all given the differences in culture at academic institutions and a variable desire for parity amongst faculty. You will need to think carefully about your priorities when approaching your negotiation. For some people, salary may be a primary issue while others may find items such as protected time or research support to be critical. Be thoughtful about what strengths you bring to the table, and do not sell yourself short. It can also be helpful to think about the negotiation from the chairperson’s point of view. How will the institution benefit from what you can bring? Oftentimes, jobs that are in highly desirable locations may be a little less flexible in negotiations if there are